Skip to main content

BWAY

Stock
Health Care
Medical Devices

Performance overview

BWAY Price
Price Chart

Forward-looking statistics

Beta
0.93
Risk
55.90%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Company info

SectorHealth Care
IndustryMedical Devices
Employees133
Market cap$107.3M

Fundamentals

Enterprise value$419.2M
Revenue$43.5M
Revenue per employee
Profit margin9.01%
Debt to equity8.73

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)$0.22
Dividend per share
Revenue per share$2.36
Avg trading volume (30 day)$540K
Avg trading volume (10 day)$761K
Put-call ratio

Macro factor sensitivity

Growth+8.2
Credit-1.2
Liquidity-4.3
Inflation+6.2
Commodities+3.2
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio132.40
Price to sales5.76
P/E Ratio132.40
Enterprise Value to Revenue9.65
Price to book7.66

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Is the Options Market Predicting a Spike in Brainsway Stock?

Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.

Zacks Investment Research (June 26, 2025)
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?

Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free